Ethical principles for psychiatric administrators: The challenge of formularies

Psychiatric Quarterly

Volumn 77, Issue 4, 2006, Pages 319-327

  Moffic, H Steven ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Administration; Formularies; Psychiatric ethics

Indexed keywords

BENZODIAZEPINE; ESCITALOPRAM; FLUOXETINE; NEUROLEPTIC AGENT; PERPHENAZINE; VALPROIC ACID;

ADMINISTRATIVE PERSONNEL; ALGORITHM; ARTICLE; CLINICAL PRACTICE; COST CONTROL; HEALTH CARE; HEALTH CARE COST; HEALTH CARE QUALITY; HUMAN; MANAGED CARE; MEDICAID; MEDICAL ETHICS; MEDICARE; MENTAL DISEASE; MENTAL HEALTH CARE; PRESCRIPTION; PSYCHIATRIC DEPARTMENT; UNSPECIFIED SIDE EFFECT;

ANTIPSYCHOTIC AGENTS; FORMULARIES; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; MANAGED CARE PROGRAMS; MEDICARE; MENTAL HEALTH SERVICES; PHYSICIAN EXECUTIVES; PRACTICE MANAGEMENT, MEDICAL; PSYCHIATRY; UNITED STATES;

EID: 33751298741     PISSN: 00332720     EISSN: 15736709     Source Type: Journal    
DOI: 10.1007/s11126-006-9017-8     Document Type: Article

References (25)

1. Sabin JE, Daniels N, Teagarden JR: The perfect storm. Psychiatric Annals 34:125-132, 2004.
2. Tennison CR: Responding to restrictive formularies. Psychiatric Annals 34:139-148, 2005.
3. Moffic HS: Managed behavioral healthcare poses multiple ethical challenges for clinicians. Psychiatric Annals 34:98-104, 2004.
4. American Psychiatric Association: The Principles of Medical Ethics with Annotations Especially Applicable to Psychiatry. Washington, DC, American Psychiatric Association, 2001.
5. Moffic HS: Ethical Principles for Psychiatric Administrators. American Association of Psychiatric Administrators Newsletter Summer:5-9, 2000.
6. Starkweather KK, Shon SP: Implementing Medication Algorithms: The Texas Experience. Psychiatrist Administrator 1(1):13-18, 2001.
7. Moffic HS: The Ethical Way: Challenges and Solutions for Managed Behavioral Healthcare. San Francisco, Jossey-Bass, 1997.
8. American Psychiatric Association Office of Healthcare Systems and Financing: Fail-First Policies - The Tip of the Pharmacy Benefit Management Iceberg 8(506):1&19, 20, 2002.
9. Sabin JE, Daniels N: Improving Psychiatric Drug Benefit Management: II. Kaiser Permanente's Approach to SSRI's. Psychiatric Services 54:1343-349, 2003.
10. Sullivan PW, Valuck R, Brixner DJ, et al: Managed Care's Response to a Pharmacoeconomic Model of Serotonin Reuptake Inhibitors. P&T 30:178-182, 2005.
11. Kanapaux W: Managed to hold down medicaid drug costs. Behavioral Healthcare Tomorrow April:22-29, 2005.
12. New Jersey Psychiatric Association: Consensus and Evidence Based Guidelines for Psychotropics in Formularies. http://www.psychnj.org/, May 10, 2005.
13. Ingoglia CS: Caring for persons with mental illness: making policy decisions that are truly cost-effective. Drug Benefit Trends Supplement 15:5-11, 2003.
14. Soumerai SB, McLaughlin TJ, Ross-Degnan D, et al: Effects of limiting medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. New England Journal of Medicine 331:650-655, 1994.
15. Frieden J: Psychiatric Formularies Not Likely to Save Money. Clinical Psychiatry News December:64, 2003.
16. Cranor CW, Bunting BA, Christensen DB: The Ashville project: long-term clinical and economic outcomes of a community pharmacy diabetes care program. Journal of the American Pharmaceutical Association 43:149-159, 2003.
17. Wassef AA, Winkler DE, Roche AL, et al: Lower effectiveness of divalproex versus valproic acid in a prospective, quasi-experimental clinical trial involving 9,260 psychiatric admissions. American Journal of Psychiatry 162:330-339, 2005.
18. Ning A, Dubin WR, Parks JJ: Pharmacy costs: Finding a role for quality. Psychiatric Services 56:909-911, 2005.
19. Lieberman JA, Stroup TS, McEvoy JP, et al: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353:1209-23, 2005.
20. Keefe RSE, Seidman LJ, Christensen BK: Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. American Journal of Psychiatry 161:985-995, 2004.
21. Stahl SM: Detecting and dealing with bias in psychopharmacology. PsychEd Up 1(4):6, 2005.
22. Baker JG: Engaging community mental health stakeholders in pharmacy cost management. Psychiatric Services 52:650-653, 2001.
23. Siris SG: Minding my own business. Psychiatric Services 56:1339, 2005.
24. Fawcett J: What we need is living treatment algorithms. Psychiatric Annals 35:873, 2005.
25. Horn S: Limiting access to psychiatric services can increase total health care costs. Drug Benefit Trends Supplement 15:12-18, 2003.